결핵 진료지침

7. Opota O, Mazza-Stalder J, Greub G, Jaton K. The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clin Microbiol Infect. 2019 Mar 28. pii: S1198–743X(19)30123–5.
8. ZifodyaJS, KreniskeJS, SchillerI, KohliM, DendukuriN, SchumacherSG, OchodoEA, HarakaF, ZwerlingAA, PaiM, SteingartKR, HorneDJ. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No.: CD009593. DOI:10.1002/14651858.CD009593.pub5.
9. World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detention, 2021 update, 2021.
10. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti- tuberculosis drug resistance in Korea, 1994–2004. Int J Tuberc Lung Dis. 2007 May;11(5):571–6.
11. Korea Disease Control and Prevention Agency. Auunual Report on the Notified Tuberculosis in Korea, 2022. 2023.
12. Kim H, Mok JH, Kang B, Lee T, Lee HK, Jang HJ, Cho YJ, Jeon D. Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study. Korean J Intern Med. 2019 Mar;34(2):344–352

I. 결핵의 진단 <PAGE>16